Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico

作者：Denisse Añorve Bailon, Francisco Javier Picó Guzmán, Sergio Cifuentes, Rogelio Trejo, Jerónimo Rafael Rodríguez‐Cid, Juan José Juárez‐Vignon Whaley, Alan Alexis Heredia Zepeda, Raquel Gerson, Christian Patricio Camacho-Limas, José Fabián Martínez‐Herrera, Diana Bonilla Molina, Efraín Sánchez, Daniela Shveid Gerson · 发表于：PharmacoEconomics - Open · 年份：2024 · DOI：10.1007/s41669-024-00514-6 · 被引用次数：4 · 研究领域：Lung Cancer Treatments and Mutations、Economic and Financial Impacts of Cancer、Lung Cancer Research Studies

INTRODUCTION: Lung cancer continues to be the leading cause of death among cancer patients worldwide. This study aimed to estimate the clinical, economic, and social burdens of stage IV non-small cell lung cancer (NSCLC) in private and public healthcare centers in Mexico, utilizing real-world evidence. METHODS: The study population included patients >18 years of age diagnosed with stage IV NSCLC who received cancer treatment at the Centro Médico Nacional Siglo XXI (IMSS), the Centro Médico Nacional "20 de Noviembre" (ISSSTE), the Mexican Institute of Respiratory Diseases (INER), and the Medical Center ABC (American British Cowdray) from 1 January 2019 to 31 December 2020. The analysis included evaluation of epidemiological data, treatment regimens, and clinical outcomes, and emphasized pharmacological and non-pharmacological treatments, including detailed follow-up investigations, as part of comprehensive clinical management. Additionally, the study assessed the social burden through variables such as working-age absenteeism and presenteeism and caregiver productivity loss, as well as economic burden, considering both clinical and social components, with costs adjusted to 2022 Mexican pesos (MXN) values. RESULTS: A total of 188 patients with metastatic NSCLC were studied. The main type of NSCLC tumor found in the sample was adenocarcinoma (81%). Treatment regimens included pharmacological treatments (78%), non-pharmacological treatments (25%), and palliative care (24%). Compl...